Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Maravai Lifesciences Holdings Inc Cl A (MRVI)

Maravai Lifesciences Holdings Inc Cl A (MRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,356,075
  • Shares Outstanding, K 252,528
  • Annual Sales, $ 288,950 K
  • Annual Income, $ -119,030 K
  • EBIT $ -44 M
  • EBITDA $ 8 M
  • 60-Month Beta -0.07
  • Price/Sales 4.69
  • Price/Cash Flow 57.34
  • Price/Book 2.23

Options Overview Details

View History
  • Implied Volatility 151.08% ( +47.76%)
  • Historical Volatility 151.93%
  • IV Percentile 99%
  • IV Rank 90.55%
  • IV High 164.54% on 10/24/24
  • IV Low 22.00% on 05/31/24
  • Put/Call Vol Ratio 0.37
  • Today's Volume 211
  • Volume Avg (30-Day) 283
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 7,809
  • Open Int (30-Day) 6,108

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.06
  • Number of Estimates 5
  • High Estimate -0.05
  • Low Estimate -0.08
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.74 +13.17%
on 11/21/24
6.13 -12.40%
on 12/02/24
+0.55 (+11.41%)
since 11/20/24
3-Month
4.28 +25.61%
on 11/18/24
8.60 -37.56%
on 09/26/24
-3.07 (-36.37%)
since 09/20/24
52-Week
4.28 +25.61%
on 11/18/24
11.56 -53.53%
on 05/17/24
-1.00 (-15.70%)
since 12/20/23

Most Recent Stories

More News
Maravai LifeSciences Appoints R. Andrew Eckert as New Chairman of the Board Following Carl Hull's Retirement

Maravai LifeSciences announces Carl Hull's retirement as Executive Chairman, appointing R. Andrew Eckert as his successor.Quiver AI SummaryMaravai LifeSciences Holdings, Inc. announced the retirement of...

MRVI : 5.37 (-1.10%)
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

MRVI : 5.37 (-1.10%)
Maravai LifeSciences Announces November 2024 Investor Conference Schedule

MRVI : 5.37 (-1.10%)
Maravai LifeSciences (MRVI) Q3 2024 Earnings Call Transcript

MRVI earnings call for the period ending September 30, 2024.

MRVI : 5.37 (-1.10%)
Maravai LifeSciences Reports Third Quarter 2024 Financial Results

MRVI : 5.37 (-1.10%)
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024

MRVI : 5.37 (-1.10%)
Maravai LifeSciences (MRVI) Q2 2024 Earnings Call Transcript

MRVI earnings call for the period ending June 30, 2024.

MRVI : 5.37 (-1.10%)
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient...

APDN : 0.1771 (-5.29%)
MRVI : 5.37 (-1.10%)
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient...

APDN : 0.1771 (-5.29%)
MRVI : 5.37 (-1.10%)
Maravai LifeSciences (MRVI) Q1 2024 Earnings Call Transcript

MRVI earnings call for the period ending March 31, 2024.

MRVI : 5.37 (-1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Maravai LifeSciences Holdings Inc. is a life sciences company providing products for the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company offer products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and...

See More

Key Turning Points

3rd Resistance Point 5.85
2nd Resistance Point 5.74
1st Resistance Point 5.55
Last Price 5.37
1st Support Level 5.25
2nd Support Level 5.14
3rd Support Level 4.95

See More

52-Week High 11.56
Fibonacci 61.8% 8.77
Fibonacci 50% 7.91
Fibonacci 38.2% 7.06
Last Price 5.37
52-Week Low 4.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar